Intuitive Surgical, Inc. $ISRG Holdings Boosted by EagleClaw Capital Managment LLC

EagleClaw Capital Managment LLC lifted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 51.2% during the third quarter, Holdings Channel.com reports. The fund owned 18,527 shares of the medical equipment provider’s stock after buying an additional 6,277 shares during the period. EagleClaw Capital Managment LLC’s holdings in Intuitive Surgical were worth $7,534,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of ISRG. Fairscale Capital LLC grew its stake in Intuitive Surgical by 3.5% in the third quarter. Fairscale Capital LLC now owns 645 shares of the medical equipment provider’s stock valued at $279,000 after purchasing an additional 22 shares in the last quarter. Beaumont Financial Advisors LLC increased its position in shares of Intuitive Surgical by 3.8% during the 3rd quarter. Beaumont Financial Advisors LLC now owns 627 shares of the medical equipment provider’s stock worth $255,000 after purchasing an additional 23 shares during the last quarter. Hughes Financial Services LLC increased its position in shares of Intuitive Surgical by 40.7% during the 3rd quarter. Hughes Financial Services LLC now owns 83 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 24 shares during the last quarter. W.G. Shaheen & Associates DBA Whitney & Co increased its position in shares of Intuitive Surgical by 1.0% during the 1st quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 2,542 shares of the medical equipment provider’s stock worth $1,172,000 after purchasing an additional 25 shares during the last quarter. Finally, Blue Fin Capital Inc. raised its stake in shares of Intuitive Surgical by 0.5% during the 1st quarter. Blue Fin Capital Inc. now owns 4,794 shares of the medical equipment provider’s stock worth $2,210,000 after purchasing an additional 25 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Trading Up 0.8%

Shares of NASDAQ ISRG opened at $443.59 on Friday. The company has a market capitalization of $153.77 billion, a P/E ratio of 53.64, a P/E/G ratio of 3.03 and a beta of 1.45. Intuitive Surgical, Inc. has a 12 month low of $328.57 and a 12 month high of $603.88. The stock has a 50 day moving average of $417.59 and a 200-day moving average of $429.98.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.35. Intuitive Surgical had a return on equity of 18.17% and a net margin of 25.54%. The business had revenue of $3.05 billion for the quarter, compared to analysts’ expectations of $2.91 billion. During the same quarter in the prior year, the business earned $2.40 EPS. The firm’s revenue for the quarter was up 21.7% on a year-over-year basis. Analysts predict that Intuitive Surgical, Inc. will post 9.37 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ISRG has been the subject of several recent analyst reports. Zacks Research raised Intuitive Surgical from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 22nd. BTIG Research restated a “buy” rating and set a $454.00 target price on shares of Intuitive Surgical in a report on Wednesday, October 21st. Piper Sandler reaffirmed an “overweight” rating on shares of Intuitive Surgical in a research report on Friday, August 21st. Citigroup cut their price target on shares of Intuitive Surgical from $590.00 to $500.00 and set a “buy” rating for the company in a research note on Friday, July 17th. Finally, TD Cowen reiterated a “buy” rating and issued a $485.00 price target on shares of Intuitive Surgical in a research note on Monday, October 19th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $493.54.

Insider Transactions at Intuitive Surgical

In other news, Director Gary Guthart sold 20,095 shares of the stock in a transaction dated Friday, October 23rd. The shares were sold at an average price of $451.61, for a total value of $9,075,102.95. Following the transaction, the director directly owned 1,204,530 shares of the company’s stock, valued at $543,977,793.30. This represents a 1.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Craig Barratt sold 1,150 shares of the stock in a transaction dated Friday, October 23rd. The shares were sold at an average price of $443.80, for a total transaction of $510,370.00. Following the completion of the transaction, the director directly owned 1,150 shares in the company, valued at $510,370. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 39,456 shares of company stock valued at $17,769,124. Corporate insiders own 0.60% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical develops, manufactures and markets robotic-assisted systems for minimally invasive procedures. Its products include da Vinci surgical systems, which allow surgeons to control instruments and a high-definition vision system from a console, as well as the Ion endoluminal system, designed to assist with minimally invasive lung biopsies. The company also provides instruments, accessories, training and support services for its systems. Its technology is used in a range of surgical specialties, including urology, general surgery and gynecology.